Taevas
United StatesPharmaceuticals
Market Intelligence
Market Intelligence for Pharmaceuticals in United States
Taevas Global equips pharmaceutical manufacturers and market entrants with the regulatory insight, competitive data, and demand analysis needed to navigate the world's largest drug market with precision. From FDA pathway mapping to pricing benchmarks, our
Market
United States
Industry
Pharmaceuticals
Service
Market Intelligence
Regulator
FDA (CDER / CBER)
Timeline
4-6 Weeks
What We Deliver
Six Pillars of United States Pharmaceuticals Intelligence
Our six interconnected intelligence pillars give pharmaceutical companies a 360-degree view of the US market, from FDA regulatory pathways to payer dynamics and competitive positioning.
01
Regulatory Landscape Analysis
We map every relevant FDA pathway for your product category, including NDA, ANDA, BLA, and 505(b)(2) routes, alongside PDUFA timelines and recent CDER and CBER guidance updates. Our analysts track Orange Book listings, patent expiries, and exclusivity periods that directly affect your launch window. This pillar ensures you enter the US market on the most efficient and defensible regulatory track.
FDA NDA, ANDA, BLA, and 505(b)(2) pathway mapping
Orange Book patent and exclusivity tracking
Recent CDER and CBER guidance and draft guidance review
How It Works
From Brief to Board-Ready Intelligence
Our four-phase engagement is designed to move from your strategic question to a decision-ready intelligence package in as little as four to six weeks.
Step 1 · Day 1-2
Discovery and Scoping
We begin with a structured briefing call to understand your product, therapeutic area, target indication, and strategic objectives. Our team documents your key questions, data gaps, decision timelines, and any existing market knowledge you hold. A detailed scope-of-work and deliverable outline is confirmed before any research begins.
Taevas Approach
The scoping session typically involves your business development, regulatory affairs, and commercial leads. We use a standardized intelligence brief template to capture product stage, competitive concerns, geographic priorities within the US, and the decisions this intelligence will directly inform. This alignment step prevents scope creep and ensures every research hour maps to a real business question.
Market Snapshot
United States Pharmaceuticals Market at a Glance
$0B
US Pharma Market Size (2023)
0%
Projected Annual Growth (CAGR)
0+
FDA-Approved Drug Manufacturers
0+
New Drug Applications Filed Annually
World's Largest Drug Market
The United States accounts for roughly 45 percent of global pharmaceutical revenues, making it the single most important market for any drug manufacturer with global ambitions. The scale of the market is matched by its complexity, with thousands of payers, formulary tiers, and channel intermediaries all shaping net realized price. Entering without granular market intelligence significantly increases the risk of pricing and access missteps.
FDA Regulatory Rigor
The FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research maintain among the most rigorous approval standards in the world, with PDUFA review timelines typically ranging from 10 to 12 months for standard reviews and 6 months for priority designations. The Orange Book and Purple Book systems create a transparent but highly competitive patent and exclusivity landscape. Understanding FDA's current enforcement priorities and guidance evolution is essential for timing your US launch correctly.
Pricing and Reimbursement Complexity
The United States lacks a single national drug pricing authority, meaning manufacturers must negotiate separately with hundreds of commercial payers, three major pharmacy benefit managers, CMS for Medicare programs, and individual state Medicaid agencies. The Inflation Reduction Act's drug price negotiation provisions for Medicare are reshaping the long-term revenue outlook for high-spend products. Mapping the access and reimbursement landscape before launch is no longer optional.
Biosimilars and Generic Competition Acceleration
The FDA's biosimilar approval pathway under the Biologics Price Competition and Innovation Act has produced a rapidly growing biosimilar market, with interchangeability designations accelerating substitution at the pharmacy level. Generic drug approvals under the ANDA pathway continue at a high volume, with the FDA actively working to reduce backlogs. Companies launching branded or innovator products must build competitive defense strategies that account for accelerated generic and biosimilar entry timelines.
What's Included
Everything in Your Report
Every Market Intelligence engagement for the US pharmaceuticals market produces eight structured deliverables designed to support decisions from regulatory strategy through commercial launch planning.
US Market Sizing Model
A fully documented, bottom-up market size model for your therapeutic area and indication, segmented by patient population, channel, and geography, with a five-year forward forecast.
FDA Regulatory Pathway Report
A detailed analysis of all applicable FDA approval pathways for your product, including NDA, ANDA, BLA, and 505(b)(2) options, with timeline estimates, fee schedules, and recent precedent approvals.
Competitive Landscape Assessment
Profiles of all key branded, generic, and biosimilar competitors in your category, including pipeline entries, market share estimates, pricing strategies, and promotional positioning.
Pricing and Reimbursement Analysis
A comprehensive review of WAC, ASP, and net price benchmarks for comparable products, alongside Medicare, Medicaid, and commercial formulary coverage analysis and access barrier scoring.
Distribution Channel Map
A visual and narrative map of the US pharmaceutical distribution ecosystem relevant to your product type, covering wholesaler, specialty pharmacy, GPO, and direct channel options with margin and logistics data.
Key Opinion Leader and Payer Insights
Synthesized findings from primary interviews with US-based KOLs, formulary decision-makers, and channel experts, presented as structured insight themes with direct quotes and implications.
Policy and Regulatory Risk Monitor
A forward-looking assessment of legislative and regulatory developments, including IRA negotiation exposure, CMS rulemaking, and state-level PBM and pricing legislation that could affect your product's commercial trajectory.
Executive Strategy Presentation
A board-ready PowerPoint deck summarizing all key findings, strategic implications, recommended market entry scenarios, and prioritized next steps for your leadership team.
Who This Is For
Built for These Situations
Market Entry
International Pharma Manufacturer Entering the US
You have a proven product in your home market and are evaluating whether and how to enter the United States. The FDA regulatory landscape, payer complexity, and competitive intensity are unfamiliar, and you need structured intelligence before committing capital to a US regulatory program or commercial buildout. Taevas Global provides the market clarity that transforms a high-risk entry decision into a calculated strategic move.
Outcome
A clear go or no-go recommendation backed by market sizing, regulatory pathway analysis, and competitive positioning data specific to your product and indication.
Next Steps
After Market Intelligence, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your United States Opportunity?
Whether you are planning your first US pharmaceutical launch or evaluating a new indication in an established market, Taevas Global delivers the intelligence you need to move forward with confidence. Request a proposal today and receive a scoping outline within 48 hours.
FDA-specific regulatory pathway analysis included in every engagement
Primary research with US payers, KOLs, and distribution channel experts
Board-ready deliverables formatted for investment committee and leadership review
30-day post-delivery support window at no additional cost